

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

PROFIT WARNING

This announcement is made by Sinopharm Tech Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on its preliminary review on the Group’s unaudited consolidated management accounts for the year ended 30 June 2020 and information currently available, it is anticipated that the Group will record an increase in net loss attributable to equity holders by not less than 230% for the year ended 30 June 2020 as compared to the audited consolidated net loss attributable to equity holders of approximately HK\$46.8 million for the year ended 30 June 2019. The Board considered that the increase in net loss attributable to equity holders for the year ended 30 June 2020 was mainly attributable to an impairment loss made on the Group’s goodwill in relation to the internet plus services and lottery-related services, which accounts for approximately 80% of the net loss attributable to equity holders.

As at the date of this announcement, the Company is still in the course of finalising its annual results of the Group for the year ended 30 June 2020. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to the information currently available to the Company. Such information has neither been confirmed nor audited by the auditors of the Company and may be subject to change. Shareholders and potential investors shall refer to the annual results of the Group for the year ended 30 June 2020 to be published on 29 September 2020.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Executive Director and Chief Executive Officer

Hong Kong, 21 September 2020

As at the date of this announcement, the Board comprises Madam CHEUNG Kwai Lan, Mr. CHAN Ting as executive Directors, Mr. CHAN Tung Mei and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.